Clinical Trial Update: Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. [Phase 1]

View source ↗

Summary

Open-label Phase 1 study evaluating the safety and preliminary efficacy of combining Rituximab with AB-101 in B-cell–associated autoimmune diseases, currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatosis with Polyangiitis
• Pemphigus Vulgaris
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus

Drugs mentioned

• AB-101
• Rituximab (rituximab)

Snippet

Sponsor: IRIS Research and Development, LLC | Conditions: Rheumatoid Arthritis, Pemphigus Vulgaris | Phase 1 | Status: RECRUITING